MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Pluristem Therapeutics Company Profile (NASDAQ:PSTI)

Consensus Ratings for Pluristem Therapeutics (NASDAQ:PSTI) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.75 (257.14% upside)

Analysts' Ratings History for Pluristem Therapeutics (NASDAQ:PSTI)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Maxim GroupReiterated RatingBuy$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016FBR & Co.Reiterated RatingOutperform$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/14/2016HC WainwrightReiterated RatingBuy$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015MLV & Co.Reiterated RatingBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2015Needham & Company LLCLower Price TargetBuy$5.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/22/2014OppenheimerInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/15/2014Jefferies GroupLower Price TargetHold$3.50 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Pluristem Therapeutics (NASDAQ:PSTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
2/10/2016        
11/24/2014($0.13)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/6/2014($0.13)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/11/2014($0.15)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/22/2014($0.14)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Pluristem Therapeutics (NASDAQ:PSTI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.10)($0.10)($0.10)
Q2 20161($0.10)($0.10)($0.10)
Q4 20161($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)
Dividend History for Pluristem Therapeutics (NASDAQ:PSTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Pluristem Therapeutics (NASDAQ:PSTI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/22/2016Zami AbermanCEOBuy5,000$1.33$6,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2016Yaky YanayCFOBuy5,000$1.20$6,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016Yaky YanayCFOBuy15,000$0.95$14,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/15/2016Doron ShorrerDirectorBuy12,346$0.81$10,000.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016Yaky YanayCFOBuy5,000$0.83$4,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2016Israel Ben-YoramDirectorBuy10,000$0.79$7,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2016Zami AbermanCEOBuy31,000$0.80$24,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Yaky YanayCFOBuy10,000$1.52$15,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Zami AbermanCEOBuy9,900$1.49$14,751.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Israel Ben-YoramDirectorSell30,000$2.10$63,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Yaky YanayCFOBuy10,000$2.11$21,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Zami AbermanCEOBuy25,500$2.11$53,805.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2015Yaky YanayCFOBuy10,000$2.12$21,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Zami AbermanCEOBuy25,000$2.11$52,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Yaky YanayCOOBuy11,000$2.62$28,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Zami AbermanCEOBuy13,000$2.64$34,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Yaky YanayCOOBuy11,000$2.95$32,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Zami AbermanCEOBuy5,000$2.92$14,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2014Zami AbermanCEOBuy5,000$2.96$14,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Israel Ben-YoramDirectorBuy5,000$2.82$14,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Boaz Gur-LavieCFOBuy3,478$2.84$9,877.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Yaky YanayCOOBuy10,000$2.85$28,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Zami AbermanCEOBuy15,000$2.80$42,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Mark GermainDirectorSell43,215$3.12$134,830.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2014Israel Ben-YoramDirectorSell35,625$4.51$160,668.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014Israel Ben-YoramDirectorSell26,453$4.29$113,483.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014Yaky YanayCFOSell69,850$4.29$299,656.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/9/2014Yaky YanayCFOSell30,150$4.25$128,137.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2014Israel Ben-YoramDirectorSell44,797$4.12$184,563.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2013Nachum RosmanDirectorSell67,244$3.27$219,887.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013Israel Ben-YoramDirectorSell52,000$3.07$159,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2013Israel Ben-YoramDirectorSell45,429$3.03$137,649.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Pluristem Therapeutics (NASDAQ:PSTI)
DateHeadline
06/30/16 08:48 AMPluristem Therapeutics, Inc. (NASDAQ:PSTI) Company Rating and Target Watch - Telanagana Press
06/29/16 05:52 PMPluristem Therapeutics Incorporated (NASDAQ:PSTI) Shorts Decreased by 11.39% After Short Covering - Press Telegraph
06/29/16 05:52 PMStrong Sell Calls Recommendations For Pluristem Therapeutics, Inc. (NASDAQ:PSTI) At 0 - Investor Newswire
06/23/16 06:34 PMPluristem Therapeutics, (NASDAQ:PSTI) presents positive data from preclinical : Canadian Solar (NASDAQ:CSIQ ... - KC Register
06/23/16 06:34 PMWednesday's Market Insights: Tesla Motors Inc (TSLA), SolarCity Corp (SCTY), Pluristem Therapeutics Inc. (PSTI ... - Smarter Analyst
06/23/16 06:34 PMPluristem Therapeutics Inc. (NASDAQ:PSTI) Nails Phase 2 Clinical Trial With PLX-PAD - Scibility Media
06/23/16 06:34 PMPluristem Therapeutics (PSTI) Catches Eye: Stock Up 11.6% - Nasdaq
06/23/16 07:15 AMPluristem Therapeutics (PSTI) Catches Eye: Stock Up 11.6% -
06/22/16 10:42 AMPluristem Reports Data Showing PLX-PAD Cells Effective in Treating Duchenne Muscular Dystrophy
06/22/16 10:42 AMPluristem Therapeutics (PSTI) Announces Positive PLX-PAD Cells Preclinical Data in DMD
06/02/16 08:57 AMBuy, Sell Or Hold Rating For Pluristem Therapeutics, Inc. (PSTI)? - Share Trading News - Buy, Sell Or Hold Rating For Pluristem Therapeutics, Inc. (PSTI)?Share Trading News12/31/2015 – Pluristem Therapeutics, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 6 price target on the stock. 12/22/2015 – Pluristem Therapeutics, Inc. had its “buy” rating reiterated by analysts ...and more »
05/31/16 03:13 PMPLURISTEM THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a -
05/29/16 10:46 PMStock Rating Review for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - HNN - Stock Rating Review for Pluristem Therapeutics, Inc. (NASDAQ:PSTI)HNNInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI). Covering ...
05/25/16 10:54 PMInsiders Are Gradually Buying Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Wall Street Hints and News - Insiders Are Gradually Buying Pluristem Therapeutics, Inc. (NASDAQ:PSTI)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Pluristem Therapeutics, Inc. (NASDAQ:PSTI) have increased their position in the stock by 1.88% over the past 6 months. Insiders now own 6.30% of total outstanding shares. There are both legal and illegal ...and more »
05/25/16 10:54 PMPluristem Therapeutics, Inc. (PSTI) Updated Broker Price Targets - Share Trading News - Pluristem Therapeutics, Inc. (PSTI) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Pluristem Therapeutics, Inc. (PSTI). The latest reports which are currently in issue on Wednesday 25th of May state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
05/24/16 10:59 PMEarnings Review and Stock Rundown for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Wall Street Hints and News - Earnings Review and Stock Rundown for Pluristem Therapeutics, Inc. (NASDAQ:PSTI)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Pluristem Therapeutics, Inc. (NASDAQ:PSTI ...and more »
05/23/16 10:47 AMStock Rating Review for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Wall Street Hints and News - Stock Rating Review for Pluristem Therapeutics, Inc. (NASDAQ:PSTI)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI). Covering ...and more »
05/22/16 05:15 PMAfter Last Week What Do Analysts Think Of Pluristem Therapeutics, Inc. (PSTI) - Share Trading News - After Last Week What Do Analysts Think Of Pluristem Therapeutics, Inc. (PSTI)Share Trading News09/15/2014 – Pluristem Therapeutics, Inc. had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 3 price target on the stock. The share price of Pluristem Therapeutics, Inc. (PSTI) was up +5.67% during the last trading session ...and more »
05/21/16 09:14 AMAlpha One Assigns Impact Score Of 0 To Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Investor Newswire - Alpha One Assigns Impact Score Of 0 To Pluristem Therapeutics, Inc. (NASDAQ:PSTI)Investor NewswireAlpha One analyzed the various web articles published on Pluristem Therapeutics, Inc. (NASDAQ:PSTI), and thereafter it gave company a daily sentiment score of 0.56. The entity designs algorithm based assessment to known stock sentiment on stock after ...and more »
05/18/16 09:59 AMShare Recap and Earnings Focus on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Wall Street Hints and News - Share Recap and Earnings Focus on Pluristem Therapeutics, Inc. (NASDAQ:PSTI)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Pluristem Therapeutics, Inc.and more »
05/16/16 05:31 PMPluristem Therapeutics (PSTI) Announces Completion of PLX-PAD Phase 2 Enrollment - StreetInsider.com - Pluristem Therapeutics (PSTI) Announces Completion of PLX-PAD Phase 2 EnrollmentStreetInsider.comPluristem Therapeutics Inc. (Nasdaq: PSTI) announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its PLacental eXpanded, PLX-PAD, cells for the treatment of intermittent claudication (IC), a peripheral artery ...Pluristem Therapeutics Completes Enrollment in Phase II Intermittent Claudication Trial (NASDAQ:PSTI)Sonoran Weekly Reviewall 3 news articles »
05/16/16 10:51 AMConsensus Rating Review for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Wall Street Hints and News - Consensus Rating Review for Pluristem Therapeutics, Inc. (NASDAQ:PSTI)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1 on shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/16/16 10:51 AMNext Weeks Broker Price Targets For Pluristem Therapeutics, Inc. (PSTI) - Share Trading News - Next Weeks Broker Price Targets For Pluristem Therapeutics, Inc. (PSTI)Share Trading NewsPluristem Therapeutics, Inc. has a 50 day moving average of 1.67 and a 200 day moving average of 1.36. The stock's market capitalization is 126.29M, it has a 52-week low of 0.71 and a 52-week high of 2.97. The share price of the company (PSTI) was up ...Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication TrialVirtual-Strategy Magazineall 29 news articles »
05/16/16 02:52 AMPluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial - [at noodls] - Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial Trial expands to randomize 20 more patients to receive two injections per patient Data release on track for 2017 ...
05/11/16 02:04 AMPluristem Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : PSTI-US : May 11, 2016 -
05/10/16 06:04 PMPerformance Recap and Target Perspective on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - B.O.D.Y Confidential - Performance Recap and Target Perspective on Pluristem Therapeutics, Inc. (NASDAQ:PSTI)B.O.D.Y ConfidentialSome investors may pay more attention to short short-term share performance, while others may be more interested in stock action over a longer period of time. In the latest trading session, shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) moved -3.70%.and more »
05/10/16 06:04 PMCheck on Analyst Ratings Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - B.O.D.Y Confidential - Check on Analyst Ratings Pluristem Therapeutics, Inc. (NASDAQ:PSTI)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 1 on shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to 5 scale.and more »
05/10/16 06:04 PMPluristem Therapeutics, Inc. (PSTI) Broker Price Targets For The Coming Week - Share Trading News - Pluristem Therapeutics, Inc. (PSTI) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Pluristem Therapeutics, Inc. (PSTI). The latest reports which are currently in issue on Tuesday 10th of May state 0 analysts have a rating of “strong buy”, 0 analysts ...Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Basic Consolidated EPS At $-0.3511Markets DailyPluristem Therapeutics Inc.: Pluristem Reports Third Quarter Fiscal 2016 Financial Highlights and Clinical ...The Wall Street TranscriptPluristem Awarded $3.3 Million Grant by Israeli GovernmentGlobeNewswire (press release)Sonoran Weekly Review -Globesall 8 news articles »
05/10/16 02:00 AMPluristem Reports Third Quarter Fiscal 2016 Financial Highlights and Clinical Development Update - [GlobeNewswire] - HAIFA, Israel, May 10, 2016-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today reported financial highlights for its fiscal third quarter ended March 31, ...
05/09/16 04:00 AMPluristem Awarded $3.3 Million Grant by Israeli Government - [GlobeNewswire] - HAIFA, Israel, May 09, 2016-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced that its wholly owned subsidiary, Pluristem Ltd., has been awarded ...
05/07/16 05:24 PMPluristem Therapeutics, Inc. (NASDAQ:PSTI) Boasts An Average Rating Of 3.5 - Investor Newswire - Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Boasts An Average Rating Of 3.5Investor NewswireAlpha One applies algorithm-based analytics for assessing a stock sentiment as per the published released on web channels. In this evaluation process, the group accesses the most relevant news platforms on a daily basis. Pluristem Therapeutics, Inc.and more »
05/04/16 11:10 PMEarnings Outlook on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - B.O.D.Y Confidential - Earnings Outlook on Pluristem Therapeutics, Inc. (NASDAQ:PSTI)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Pluristem Therapeutics, Inc. (NASDAQ:PSTI)'s next earnings release which is expected to be posted on or around 2016-05-04. Sell-side research firms on Wall Street are expecting that the company will post EPS ...and more »
05/02/16 06:29 PMAverage Analyst Rating for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - B.O.D.Y Confidential - Average Analyst Rating for Pluristem Therapeutics, Inc. (NASDAQ:PSTI)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/02/16 06:29 PMHot Watch List: Pluristem Therapeutics, Inc. (NASDAQ:PSTI), Fortress Biotech, Inc. (NASDAQ:FBIO), Gladstone ... - KC Register - Hot Watch List: Pluristem Therapeutics, Inc. (NASDAQ:PSTI), Fortress Biotech, Inc. (NASDAQ:FBIO), Gladstone ...KC RegisterPluristem Therapeutics, Inc. (NASDAQ:PSTI) announced that it has entered into a licensing agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to obtain a key patent in Japan to cover the treatment of ischemic ...
05/02/16 06:29 PMThis Weeks Broker Price Targets For Pluristem Therapeutics, Inc. (PSTI) - Share Trading News - This Weeks Broker Price Targets For Pluristem Therapeutics, Inc. (PSTI)Share Trading NewsPluristem Therapeutics, Inc. has a 50 day moving average of 1.66 and a 200 day moving average of 1.37. The stock's market capitalization is 143.08M, it has a 52-week low of 0.71 and a 52-week high of 2.97. The share price of the company (PSTI) was up ...and more »
04/30/16 05:59 PMPluristem Therapeutics, Inc. (NASDAQ:PSTI) Has An Impact Score Of 100 - Investor Newswire - Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Has An Impact Score Of 100Investor NewswirePluristem Therapeutics, Inc. (NASDAQ:PSTI) has been given a 0 daily sentiment score for the related articles published on web today. Alpha One offer algorithm-based analytics, which can help state stock sentiment based on the content published on ...and more »
04/29/16 11:26 PMLatest Analyst Ratings For Pluristem Therapeutics, Inc. (PSTI) - Share Trading News - Latest Analyst Ratings For Pluristem Therapeutics, Inc. (PSTI)Share Trading NewsPluristem Therapeutics, Inc. has a 50 day moving average of 1.65 and a 200 day moving average of 1.37. The stock's market capitalization is 141.48M, it has a 52-week low of 0.71 and a 52-week high of 2.97. The share price of the company (PSTI) was up ...Pluristem Therapeutics Incorporated (NASDAQ:PSTI) Shorted Shares Increased By 8.97%The Postall 4 news articles »
04/28/16 06:27 PMBroker Outlook For Pluristem Therapeutics, Inc. (PSTI) - Share Trading News - Broker Outlook For Pluristem Therapeutics, Inc. (PSTI)Share Trading NewsPluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company developing off-the-shelf allogeneic cell therapy products for the treatment of multiple ischemic and inflammatory conditions. The Company focuses on cardiovascular, orthopedic ...
04/27/16 11:31 PMPluristem Therapeutics Incorporated (NASDAQ:PSTI) Shorted Shares Increased By 8.97% - The Post - Pluristem Therapeutics Incorporated (NASDAQ:PSTI) Shorted Shares Increased By 8.97%The PostThe short interest to Pluristem Therapeutics Incorporated's float is 1.16%. The stock decreased 2.21% or $0.04 on April 27, hitting $1.77. About 119,532 shares traded hands. Pluristem Therapeutics Inc. (NASDAQ:PSTI) has declined 12.87% since September ...and more »
04/26/16 06:23 PMShare Performance and Target Price Review Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - B.O.D.Y Confidential - Share Performance and Target Price Review Pluristem Therapeutics, Inc. (NASDAQ:PSTI)B.O.D.Y ConfidentialDuring the most recent trading session, shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) ended up with a move of -2.16%. Sell-side analysts have given a consensus target price of $4.33 on company shares. Target price projections may differ greatly ...and more »
04/22/16 11:33 PMPluristem Therapeutics Incorporated (NASDAQ:PSTI) Short Interest Increased By 8.97% - The Post - Pluristem Therapeutics Incorporated (NASDAQ:PSTI) Short Interest Increased By 8.97%The PostThe short interest to Pluristem Therapeutics Incorporated's float is 1.16%. The stock increased 1.14% or $0.02 on April 22, hitting $1.77. About 77,053 shares traded hands. Pluristem Therapeutics Inc. (NASDAQ:PSTI) has declined 16.51% since September ...and more »
04/22/16 06:27 PMPluristem Therapeutics, Inc. (NASDAQ:PSTI) Analyst Rating Review - B.O.D.Y Confidential - Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Analyst Rating ReviewB.O.D.Y ConfidentialCovering analysts typically give Buy, Sell and Hold recommendations along with guidance and company earnings projections. Currently, there are 3 analysts that have provided ratings for Pluristem Therapeutics, Inc. (NASDAQ:PSTI). 3 have rated the stock ...
04/22/16 06:27 PMPluristem Therapeutics, Inc. (NASDAQ:PSTI) Share Rating Recap - The Post - Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Share Rating RecapThe PostShares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...and more »
04/21/16 06:27 PMPluristem Therapeutics (PSTI) Enters into Licensing Agreement with TES Holdings Co - StreetInsider.com - Pluristem Therapeutics (PSTI) Enters into Licensing Agreement with TES Holdings CoStreetInsider.comPluristem Therapeutics Inc. (Nasdaq: PSTI) today announced that it has entered into a licensing agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to obtain a key patent in Japan to cover the treatment of ...Pluristem Therapeutics Signs Licensing Deal with TES Holdings for Placental Cell Therapy Patent (NASDAQ:PSTI)Sonoran Weekly Reviewall 2 news articles »
04/21/16 03:00 AMPluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease an - [GlobeNewswire] - HAIFA, Israel, April 21, 2016-- Pluristem Therapeutics Inc., a leading developer of placenta-derived cell therapy products, today announced that it has entered into a licensing agreement with TES Holdings ...
04/14/16 06:28 PMPluristem Therapeutics, Inc. (NASDAQ:PSTI) Analyst Recommendation Outlook - Clinton Financial - Clinton FinancialPluristem Therapeutics, Inc. (NASDAQ:PSTI) Analyst Recommendation OutlookClinton FinancialCovering analysts usually give Buy, Sell and Hold recommendations along with guidance and company earnings estimates. There are 3 analysts providing ratings for Pluristem Therapeutics, Inc. (NASDAQ:PSTI). 3 have given the stock a “Strong Buy”, 0 rate ...Can Shares Of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Hit $6?Equities Focusall 349 news articles »
03/02/16 08:00 AMPluristem's Radiation Antidote Bests Blockbuster Drug Neupogen - [Accesswire] - PLX-R18 Heals 100% of Population Exposed To Lethal Radiation through Nuclear Accident or Attack; Ready To Supply U.S. Government NEW YORK, NY / ACCESSWIRE / March 2, 2016 / A new cell therapy can heal ...
02/17/16 03:24 PMPluristem Therapeutics, Inc. Earnings Analysis: Q2, 2016 By the Numbers -
02/16/16 07:00 AMNational Institutes of Health’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome - [GlobeNewswire] - HAIFA, Israel, Feb. 16, 2016-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced that the National Institute of Allergy and Infectious Diseases, ...
02/12/16 12:04 PMPLURISTEM THERAPEUTICS INC Financials -
About Pluristem Therapeutics

Pluristem Therapeutics logoPluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company developing off-the-shelf allogeneic cell therapy products for the treatment of multiple ischemic and inflammatory conditions. The Company focuses on cardiovascular, orthopedic, pulmonary, hematological and women's health diseases. The Company is focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's placenta expanded (PLX) cells are intended to function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals that are generated by the patient's own body. PLX cells are grown using its three-dimensional (3D), micro environment technology, which produces a product that requires no tissue matching prior to administration. Its PLX products are in clinical-stage development for multiple indications.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PSTI
  • CUSIP:
Key Metrics:
  • Previous Close: $1.34
  • 50 Day Moving Average: $1.47
  • 200 Day Moving Average: $1.35
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $107.42M
  • Current Quarter EPS Consensus Estimate: $-0.30 EPS
Additional Links:
Pluristem Therapeutics (NASDAQ:PSTI) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha